Deerfield Management Company, L.P. (Series C) Biocryst Pharmaceuticals Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 8,144,442 shares of BCRX stock, worth $68.1 Million. This represents 1.52% of its overall portfolio holdings.
Number of Shares
8,144,442
Previous 8,135,804
0.11%
Holding current value
$68.1 Million
Previous $61.8 Million
0.95%
% of portfolio
1.52%
Previous 1.15%
Shares
25 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$167 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$99.2 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$76 Million4.33% of portfolio
-
State Street Corp Boston, MA7.5MShares$62.7 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.55B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...